ALK and non-small cell lung carcinoma: The FDA approved crizotinib firstly for the treatment of patients with metastatic or locally advanced ALK-positive NSCLC on August 26, 2011, based on the results of two clinical trials, including a phase I study (PROFILE 1001, NCT00585195) and a phase II study (PROFILE 1005, NCT00932451), which filled the gap of targeted therapies in the field of ALK-positive NSCLC at that time [166].